OasisLMS

Description 

Pharmacogenomics continues to be a growing area within the practice of psychiatry, with increasing research, testing availability, and guidance on utilization.   This presentation will provide an up to date review of the current state of evidence on the use of pharmacogenomic testing in psychiatry, including a brief review of pharmacogenomics to level the playing field in the remaining discussion, a contrast of current available testing- commercial versus research, discussion of current utilization of testing in clinical practice- what do the guidelines, clinical trials, and package inserts recommend, and finally how to consider implementation of pharmacogenomics in practice- what should a provider consider prior to ordering and how to interpret the results after receiving them.  Resources will be provided on evidence and interpretation. 

Format  

Recorded webinar, non-interactive, self-paced distance learning activity with post-test.  

This presentation was recorded on November 3, 2023. 

Learning Objectives 

Describe pharmacogenomics in the current literature regarding the treatment of serious mental illness. 

Contrast available pharmacogenomic tests. 

Describe current utilization of pharmacogenomic testing in clinical practice. 

Discuss implementation of pharmacogenomic testing in practice. 

Target Audience 

Psychiatrist, Physician (Non-psychiatrist), Physician Assistant, Nurse/Nurse Practitioner, Pharmacist 

Instructional Level 

Intermediate 

Estimate Time to Complete 

Estimated Duration: 1.0 hour 
Program Start Date: July 30, 2025
Program End Date: July 30, 2028

Ongoing Interdisciplinary Discussion Board 

After completing the course, engage with colleagues in the mental health field through the Webinar Roundtable Topics discussion board. This is an easy way to network and share ideas with other clinicians who participate in this webinar. Access through the discussion tab.  

How to Earn Credit 

After evaluating the activity, participants will be provided with an opportunity evaluate the activity and, claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned. 

Continuing Education Credit 

In support of improving patient care, American Psychiatric Association (APA) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Physicians   

The APA designates this live event for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Nurses/Nurse Practitioners   

The American Psychiatric Association (APA) designates this activity for 1.00 Nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.   

Pharmacists   

This curriculum has been approved for 1.0 contact hour (.1 CEU) by the American Psychiatric Association.  The American Psychiatric Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN: JA0000145-0000-23-012-L99-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).    

Faculty and Planner Disclosures 

The American Psychiatric Association adheres to the ACCME's Standards for Integrity and Independence in Accredited Medical Education. Any individuals in a position to control the content of a CME activity - including faculty, planners, reviewers, or others - are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.  

Faculty 

Megan Ehret, PharmD, MS, BCPP is an Associate Professor at University of Maryland, School of Pharmacy. Dr. Ehret completed her BS and PharmD degrees from the University of Toledo. Additionally, Dr. Ehret received her Master in Clinical and Translational Research from the University of Connecticut Health Center. Dr. Ehret is also a Board-Certified Psychiatric Pharmacist. Most recently Dr. Ehret has practiced at Fort Belvoir Community Hospital as their Behavioral Health Clinical Pharmacy Specialist. She has experience in treating the spectrum of mental illnesses and substance use disorders. Additionally, she is President-Elect for the College of Psychiatric and Neurologic Pharmacists (CPNP) and serves as the Senior Editor on the Psychiatric Pharmacotherapy Review Course. Dr. Ehret has no relevant financial relationships to disclose.  

Planners